BIBW2992 further delays tumor progression by maintaining irreversible binding to EGFR and HER2, maintaining longer activity, suppressing transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib [115, 116]. Here, EGFR is linked to lung cancer.